TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

--iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of ...

Today's biotech news roundup includes thoughts on hopes for TIGIT and questions about Summit Therapeutics' ivonescimab data in lung cancer.

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell ...

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the ...